(Q30960709)

27 June 2017

1 reference

title

Assessing treatment effects on axonal loss--evidence from MRI monitored clinical trials (English)

1 reference

27 June 2017

Frederik Barkhof

1 reference

27 June 2017

publication date

1 September 2004

1 reference

27 June 2017

1 reference

27 June 2017

volume

251 Suppl 4

1 reference

27 June 2017

page(s)

IV6-12

1 reference

Cerebral atrophy and disability in relapsing-remitting and secondary progressive multiple sclerosis over four years

27 June 2017

cites work

1 reference

12 December 2020

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadi

1 reference

12 December 2020

Evidence of early cortical atrophy in MS: relevance to white matter changes and disability

1 reference

12 December 2020

Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes".

1 reference

12 December 2020

Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis

1 reference

12 December 2020

Spinal cord atrophy and disability in multiple sclerosis over four years: application of a reproducible automated technique in monitoring disease progression in a cohort of the interferon beta-1a (Rebif) treatment trial

1 reference

12 December 2020

Cognitive performance and MR markers of cerebral injury in cognitively impaired MS patients

1 reference

12 December 2020

Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients

1 reference

12 December 2020

Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis.

1 reference

12 December 2020

Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Beta-Interferon treatment does not always slow the progression of axonal injury in multiple sclerosis

1 reference

12 December 2020

T(1) hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment

1 reference

12 December 2020

The emerging role of MRI in multiple sclerosis and the new diagnostic criteria

1 reference

12 December 2020

Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b.

1 reference

12 December 2020

The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis.

1 reference

12 December 2020

Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions

1 reference

12 December 2020

Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group

1 reference

12 December 2020

The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis.

1 reference

12 December 2020

Correlation of magnetic resonance imaging parameters with clinical disability in multiple sclerosis: a preliminary study

1 reference

12 December 2020

Brain MRI lesions and atrophy are related to depression in multiple sclerosis

1 reference

12 December 2020

Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications

1 reference

12 December 2020

Focal thinning of the cerebral cortex in multiple sclerosis

1 reference

12 December 2020

Early N-acetylaspartate depletion is a marker of neuronal dysfunction in rats and primates chronically treated with the mitochondrial toxin 3-nitropropionic acid

1 reference

12 December 2020

The clinico-radiological paradox in multiple sclerosis revisited

1 reference

12 December 2020

Eight-year follow-up study of brain atrophy in patients with MS.

1 reference

12 December 2020

Quality of life and its relationship to brain lesions and atrophy on magnetic resonance images in 60 patients with multiple sclerosis.

1 reference

12 December 2020

1H-MRS in patients with multiple sclerosis undergoing treatment with interferon beta-1a: results of a preliminary study

1 reference

12 December 2020

T1 hypointense lesion load in secondary progressive multiple sclerosis: a comparison of pre versus post contrast loads and of manual versus semi automated threshold techniques for lesion segmentation

1 reference

12 December 2020

Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance

1 reference

12 December 2020

Magnetic resonance imaging outcome of new enhancing lesions in relapsing-remitting multiple sclerosis patients treated with interferon beta1a.

1 reference

12 December 2020

Comparison of MS clinical phenotypes using conventional and magnetization transfer MRI.

1 reference

12 December 2020

A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon beta-1a. Multiple Sclerosis Collaborative Research Group

1 reference

12 December 2020

Statistics for investigation of multimodal MR imaging data and an application to multiple sclerosis patients

1 reference

12 December 2020

Disturbed function and plasticity in multiple sclerosis as gleaned from functional magnetic resonance imaging

1 reference

12 December 2020

A Longitudinal Study of Abnormalities on MRI and Disability from Multiple Sclerosis

1 reference

12 December 2020

Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS.

1 reference

12 December 2020

MRI measures and their relations with clinical disability in relapsing-remitting and secondary progressive multiple sclerosis

1 reference

12 December 2020

Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis

1 reference

12 December 2020

Neurotrophic cross-talk between the nervous and immune systems: implications for neurological diseases

1 reference

12 December 2020

Neuronal damage in T1-hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy

1 reference

12 December 2020

Gadolinium enhanced MRI predicts clinical and MRI disease activity in relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Bicaudate ratio as a magnetic resonance imaging marker of brain atrophy in multiple sclerosis

1 reference

12 December 2020

Regional brain atrophy is associated with physical disability in multiple sclerosis: semiquantitative magnetic resonance imaging and relationship to clinical findings

1 reference

12 December 2020

Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients

1 reference

12 December 2020

10.1007/S00415-004-1403-2

Identifiers

DOI

0 references

Dimensions Publication ID

1044654539

0 references

Fatcat ID

release_u2ed2u46onggnej3wdpz7cej5u

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/u2ed2u46onggnej3wdpz7cej5u

24 November 2022

mapped directly with Wikidata item

1 reference